2022
DOI: 10.1016/j.critrevonc.2022.103621
|View full text |Cite
|
Sign up to set email alerts
|

The role of PARP inhibitors in gastrointestinal cancers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 91 publications
0
5
0
Order By: Relevance
“…Targeting various components of the DNA Damage Repair (DDR) pathway, such as PARP, ATM, ATR, CHK1, WEE1, and DNA-PK, has led to the development of DDR-targeted drugs, some of which are currently under clinical study (35,36). Currently, inhibitors of these DDR components, some of which are under clinical study (37,38). It's also interesting to note the potential synergy between DDR inhibitors and conventional cancer therapies, as well as their correlation with immune checkpoint inhibitor response, which promotes the exploration of combination therapies.…”
Section: Discussionmentioning
confidence: 99%
“…Targeting various components of the DNA Damage Repair (DDR) pathway, such as PARP, ATM, ATR, CHK1, WEE1, and DNA-PK, has led to the development of DDR-targeted drugs, some of which are currently under clinical study (35,36). Currently, inhibitors of these DDR components, some of which are under clinical study (37,38). It's also interesting to note the potential synergy between DDR inhibitors and conventional cancer therapies, as well as their correlation with immune checkpoint inhibitor response, which promotes the exploration of combination therapies.…”
Section: Discussionmentioning
confidence: 99%
“…Patients with P/LP variants in HR pathway genes tended to have a higher proportion of elevated serum CEA, metastatic lymph nodes and cancer nodules, and a lower proportion of multiple primary CRC. Compared to patients without germline mutations, HR pathway gene mutation carriers had worse PFS and OS rates, possibly due to the lack of targeted therapies for HR gene mutations in CRC 45 . FAP patients are readily identi able due to their notable phenotype of multiple colonic adenomas 46 .…”
Section: Discussionmentioning
confidence: 99%
“…Patients with P/LP variants in HR pathway genes tended to have a higher proportion of elevated serum CEA, metastatic lymph nodes, and cancer nodules, and a lower proportion of multiple primary CRC. Compared to patients without germline mutations, HR pathway gene mutation carriers had worse PFS and OS rates, possibly due to the lack of targeted therapies for HR gene mutations in CRC [ 33 ]. FAP patients are distinguishable by their characteristic multitude of colonic adenomas [ 34 ].…”
Section: Discussionmentioning
confidence: 99%